TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cryo-Cell International ( (CCEL) ) has shared an update.
Cryo-Cell International announced that it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The decision reflects the company’s consideration of financial performance, capital requirements, and strategic priorities, indicating a flexible approach to future dividend declarations.
The most recent analyst rating on (CCEL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.
Spark’s Take on CCEL Stock
According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.
Cryo-Cell International’s overall stock score is primarily influenced by its financial performance and technical analysis. The company faces significant financial challenges, including declining revenue and high leverage, which are reflected in the low financial performance score. Technical analysis indicates bearish momentum, further impacting the score. The high dividend yield provides some support, but the negative P/E ratio highlights earnings concerns.
To see Spark’s full report on CCEL stock, click here.
More about Cryo-Cell International
Cryo-Cell International operates in the biotechnology industry, focusing on the preservation of umbilical cord blood and tissue for potential future medical use.
Average Trading Volume: 16,493
Technical Sentiment Signal: Sell
Current Market Cap: $34.23M
See more insights into CCEL stock on TipRanks’ Stock Analysis page.